ATLANTIS trial

Results for patients treated within 3 hours of stroke onset

Gregory W. Albers, Wayne Clark, Kenneth P. Madden, Scott A. Hamilton

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

Original languageEnglish (US)
Pages (from-to)493-495
Number of pages3
JournalStroke
Volume33
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Tissue Plasminogen Activator
Stroke
Therapeutics
Intracranial Hemorrhages
National Institutes of Health (U.S.)
Placebos

Keywords

  • Stroke, acute
  • Thrombolysis
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

ATLANTIS trial : Results for patients treated within 3 hours of stroke onset. / Albers, Gregory W.; Clark, Wayne; Madden, Kenneth P.; Hamilton, Scott A.

In: Stroke, Vol. 33, No. 2, 2002, p. 493-495.

Research output: Contribution to journalArticle

Albers, Gregory W. ; Clark, Wayne ; Madden, Kenneth P. ; Hamilton, Scott A. / ATLANTIS trial : Results for patients treated within 3 hours of stroke onset. In: Stroke. 2002 ; Vol. 33, No. 2. pp. 493-495.
@article{63fb694c8749405f95a1fdc10fe0440e,
title = "ATLANTIS trial: Results for patients treated within 3 hours of stroke onset",
abstract = "Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.",
keywords = "Stroke, acute, Thrombolysis, Tissue plasminogen activator",
author = "Albers, {Gregory W.} and Wayne Clark and Madden, {Kenneth P.} and Hamilton, {Scott A.}",
year = "2002",
doi = "10.1161/hs0202.102599",
language = "English (US)",
volume = "33",
pages = "493--495",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - ATLANTIS trial

T2 - Results for patients treated within 3 hours of stroke onset

AU - Albers, Gregory W.

AU - Clark, Wayne

AU - Madden, Kenneth P.

AU - Hamilton, Scott A.

PY - 2002

Y1 - 2002

N2 - Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

AB - Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

KW - Stroke, acute

KW - Thrombolysis

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=0036158585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036158585&partnerID=8YFLogxK

U2 - 10.1161/hs0202.102599

DO - 10.1161/hs0202.102599

M3 - Article

VL - 33

SP - 493

EP - 495

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 2

ER -